# OnCo record bcr-abl1-t315i (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/bcr-abl1-t315i/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "bcr-abl1-t315i" ;
  schema:name "BCR::ABL1 T315I"@en ;
  schema:alternateName "T315I"@en, "BCR-ABL T315I"@en, "ABL1 T315I"@en, "T315I mutation"@en, "gatekeeper mutation CML"@en ;
  schema:description "T315I is the gatekeeper mutation in the ABL1 kinase that defeats imatinib, dasatinib, nilotinib and bosutinib. Ponatinib and asciminib are the two drugs approved for it."@en ;
  schema:url <https://onco.cc/biomarkers/bcr-abl1-t315i/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e33001e7-3650-42b1-ae56-cddb5c43aa2b>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16d804b6-4957-43ee-b18c-3b36ec37c5ac> ;
  onco:tag "biomarker", "cml", "resistance" ;
  onco:related <https://onco.cc/biomarkers/bcr-abl1-transcript/> ;
  onco:cancers <https://onco.cc/cancers/cml/>, <https://onco.cc/cancers/cml-chronic-phase/>, <https://onco.cc/cancers/cml-advanced-phase/>, <https://onco.cc/cancers/all-leukemia/> ;
  onco:drugs <https://onco.cc/drugs/ponatinib/>, <https://onco.cc/drugs/asciminib/> ;
  onco:terms <https://onco.cc/terms/abl1-kinase-domain-mutations/>, <https://onco.cc/terms/gatekeeper-mutation/> .